Investigational Site Number 4016 — New York, New York

Investigational Site Number 4016 is a clinical research site located in New York, New York, United States 10029.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Investigational Site Number 4016 has participated in 1 clinical trials.

Therapeutic areas: Primary Focal Segmental Glomerulosclerosis.

Sponsors: Genzyme, a Sanofi Company.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Investigational Site Number 4016?

Investigational Site Number 4016 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Investigational Site Number 4016 conducted?

Investigational Site Number 4016 has 1 clinical trials on record. Their work covers Primary Focal Segmental Glomerulosclerosis.

Is Investigational Site Number 4016 accredited by Crixeo Health?

Investigational Site Number 4016 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Investigational Site Number 4016?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.